A letter to our Shareholders, May 2020
Our present...Our future.
Our Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge.
CITI-002 is a topical formulation of halobetasol and lidocaine that is intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids. In the United States, hemorrhoids affect nearly 5% of the population, with approximately 10 million patients annually reporting symptoms.
Citius is dedicated to building a successful pharmaceutical company through the development and commercialization of innovative and cost-effective products that address compelling market opportunities. We believe our 505(b)(2) expertise can assist in obtaining rapid approvals of novel products.
A Message for the Investment Community
For the most recent update on Company activities, please click the button below to download our latest Shareholders Letter.
Visit our Investor Relations site to stay up-to-date on our latest development and commercialization news.
Citius Publishes Expert Roundtable on Catheter-Related Bacteremias
Citius commissioned a roundtable of leading specialists to discuss the treatment of catheter-related bacteremias, focusing on the issue of the source of the bacteremia: the infected central venous catheter. The roundtable brought the disciplines of venous nursing care and interventional vascular management to the core specialty of Infectious Disease.
The highlights of that roundtable are presented in the sponsored publication, “Treating CLABSI: A Clinical and Economic Challenge.”
Citius Pharmaceuticals RSS News
- Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
- Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference
- Citius Pharmaceuticals to Present at the LD 500 Virtual Conference
- Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap
- Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo
- Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
- Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
- Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
- Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
- Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
- Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event
- Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
- FDA Expediting Accelerated Development of Novel Therapies for COVID-19
- Novel Stem Cell Therapy for COVID-19-related ARDS in Development
- Citius to License Novellus’ iPSC-derived MSCs for COVID-19 Related Complications
- Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS
- BRIEF-Citius Signs Exclusive Option With Novellus To License Novel Stem-Cell Therapy For Acute Respiratory Distress Syndrome (Ards) Associated With Covid-19
- Citius Signs Option With Novellus To License Novel Stem-Cell Therapy For ARDS
- Vaccine for COVID-19 Health Crises "Possible" by Summer After FDA Fast-Tracks Clinical Trials
- Citius, Novellus Ink COVID-19 Pact
- Listen to the interview with CEO and President: Myron Holubiak of Citius Pharmaceuticals (NASDAQ: CTXR)
- H.C. Wainwright Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR)
- Citius Pharmaceuticals (NASDAQ: CTXR) CEO provides update on their key products